|
19
|
|
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks: a phase 3, multicentre, randomised, double-blind, placebo-controlled crossover trial.
(linkinghub.elsevier.com)
|
Riedl MA
…
Cohn DM
The Lancet
2026-10-08
|
#angioedema
#clinical trial
#hereditary
#pharmacotherapy
#bradykinin
|
|
12
|
|
Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.
(nature.com)
|
Guo L
…
Ye Z
Nature Medicine
2026-10-05
|
#diabetes
#clinical trial
#pharmacotherapy
#glycemic control
|
|
4
|
|
Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
(nejm.org)
|
Wharton S
…
Kaplan LM
New England Journal of Medicine
2026-10-01
|
#clinical trial
#diabetes
#obesity
#pharmacotherapy
#metabolism
|
|
3
|
|
Smoking Cessation Among Underserved Patients Referred for Lung Cancer Screening: A Randomized Clinical Trial.
(jamanetwork.com)
|
Hart JL
…
Halpern SD
JAMA
2026-10-05
|
#lung cancer
#smoking-cessation
#behavioral-intervention
#pharmacotherapy
#health disparities
|
|
2
|
|
Pharmacologic Treatments for Female Menopausal Vasomotor Symptoms: A Systematic Review and Meta-analysis for the American College of Physicians.
(acpjournals.org)
|
Diem S
…
Wilt TJ
Annals of Internal Medicine
2026-10-06
|
#menopause
#meta-analysis
#pharmacotherapy
#vasomotor
#hormone therapy
|
|
2
|
|
Pharmacologic Treatments for Females With Menopausal Vasomotor Symptoms: A Clinical Guideline From the American College of Physicians.
(acpjournals.org)
|
Qaseem A
…
Cross JT Jr
Annals of Internal Medicine
2026-10-06
|
#menopause
#pharmacotherapy
#vasomotor
#guideline
|
|
2
|
|
Oral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trial.
(nature.com)
|
Yu M
…
Xiao X
Nature Medicine
2026-09-29
|
#diabetes
#clinical trial
#glp-1 agonist
#pharmacotherapy
#glycemic control
|
|
2
|
|
Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.
(nejm.org)
|
Jastreboff AM
…
Wang Y
New England Journal of Medicine
2026-09-29
|
#obesity
#pharmacotherapy
#agonist
#metabolism
|
|
2
|
|
Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial.
(linkinghub.elsevier.com)
|
Klein KR
…
Meskimen ER
The Lancet
2026-09-30
|
#diabetes
#cardiovascular
#safety
#glp-1
#pharmacotherapy
|
|
1
|
|
Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.
(linkinghub.elsevier.com)
|
Bellido V
…
Taylor A
The Lancet
2026-09-29
|
#clinical trial
#diabetes
#obesity
#pharmacotherapy
|